According to AstraZeneca, the European Commission has approved the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of the product in September 2014, and AstraZeneca acquired the rights to commercialize the inhaler in the EU when it acquired Almirall’s respiratory business earlier this year.
AstraZeneca Executive VP, Global Medicines Development and Chief Medical Officer Briggs Morrison commented, “We are pleased to receive European regulatory approval for Duaklir Genuair as an innovative treatment for patients with COPD. Patients need treatments that can help to improve their lung function and allow them to better manage the daily and debilitating symptoms of their condition, in turn improving their overall quality of life.”
Read the AstraZeneca press release.
